Lung cancer combo trial halted early – what we know

NCT ID NCT04396535

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding bintrafusp alfa (an immunotherapy) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer who have already tried other treatments. Only 10 people took part before the study was stopped early. The goal was to see if the combination could slow cancer growth better than chemo alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Docetaxel and bintrafusp alfa
What this could lead to
If successful, this combination could offer a new treatment option for advanced lung cancer patients who have already tried standard therapies.
What could go wrong
The trial was terminated early with only 10 participants, so results are very limited. It is unclear if the combination is better than docetaxel alone, and side effects from both drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.